Answers are grounded in this paper and cite their sources.
BACKGROUND: The aim of this study was to determine whether the combined use of the C-reactive protein (CRP) level and neutrophil-lymphocyte ratio (NLR) before treatment predicts disease-specific survival in adult patients with soft tissue sarcoma (STS). METHODS: We retrospectively reviewed 142 patients who presented with STS between 1995 and 2010. RESULTS: The NLR varied from 0.54 to 7.59. An elevated CRP level was observed in 36 patients before treatment. The patients with both an elevated CRP level and high NLR had a poorer disease-specific survival (46% at 5 years) than the patients with both a normal CRP level and low NLR (87% at 5 years) (P = 0.0005). The patients with both an elevated CRP level and high NLR also had a poorer disease-specific survival than the patients with either an elevated CRP level or high NLR (75.6% at five years) (P = 0.03). There were no significantly prognostic differences between the patients with a normal CRP level and low NLR and those with either an elevated CRP level or high NLR (P = 0.18). A multivariate analysis also showed the preoperative NLR and CRP level to be independent predictors of survival. CONCLUSIONS: We recommend the routine measurement of these markers to identify patients with a greater risk of death.
No takes yet. Share an insight, caveat, or question.
Nakamura et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: